In my last column, I addressed the growing trend of both providers and manufacturers turning to litigation to resolve key areas of debate in the 340B program—a significant departure from how the program worked for close to three decades when … [Read more...]
Why the Courts Have Become the Last Refuge for 340B Providers
March 17, 2026 by
During my 22 years in leadership at the trade group for 340B hospitals, rarely did we ever have to threaten—or actually take—legal action against a government policy or drug industry action. Times have certainly changed. It seems like … [Read more...]